MGC Pharmaceuticals Ltd.

Journal of Cellular and Molecular Medicine publish academic paper on Effect of ArtemiC™ in patients with COVID-19

20 May 2022

ASX, LSE: MXC

Key Highlights:

·    Journal of Cellular and Molecular Medicine have published a study into the effect of MGC Pharma's proprietary product ArtemiC™ in patients with Covid-19.

·    The Phase II prospective study is peer reviewed and is available for all to read

·    This is the first clinical study addressing the safety and tolerability of ArtemiC oral spray and its efficacy in improving symptoms in hospitalized COVID-19 patients.

·    These findings suggest that ArtemiC curbed deterioration, possibly by limiting the cytokine storm of COVID-19.

MGC Pharmaceuticals Ltd (ASX, LSE: MXC, 'MGC Pharma' or 'the Company'), a European based bio-pharma company specialising in the production and development of phytomedicines, has had a peer reviewed paper into the Effect of ArtemiC™ in patients with COVID-19 published in the Journal of Cellular and Molecular Medicine.

The Phase II prospective study of 50 patients all with COVID-19 concludes that "ArtemiC curbed deterioration, possibly by limiting the cytokine storm of COVID-19, and bears great promise for COVID-19 patients, particularly in those with comorbidities."

This is the first clinical study addressing the safety and tolerability of ArtemiC™ oral spray and its efficacy in improving symptoms in hospitalized COVID-19 patients and the first scientific article published on ArtemiC™.

The article is open access, and can be read in the Journal of Cellular and Molecular Medicine at the link below:

https://onlinelibrary.wiley.com/doi/10.1111/jcmm.17337

--Ends-

Authorised for release by the Managing Director, for further information please contact:

About MGC Pharma

MGC Pharmaceuticals Ltd (LSE: MXC, ASX: MXC) is a European based bio-pharma company developing and supplying affordable standardised phytomedicines to patients globally.  The Company's founders were key figures in the global medical cannabis industry and the core business strategy is to develop and supply high quality phytocannabinoid derived medicines for the growing demand in the medical markets in Europe, North America and Australasia. MGC Pharma has a robust product offering targeting two widespread medical conditions - Epilepsy and Dementia - and has further products in the development pipeline. 

Employing its 'Nature to Medicine' strategy, MGC Pharma has partnered with renowned institutions and academia to optimise cultivation and the development of targeted phytocannabinoid derived medicines products prior to production in the Company's EU-GMP Certified manufacturing facility.  

MGC Pharma has a number of research collaborations with world renowned academic institutions, and including recent research highlighting the positive impact of using specific phytocannabinoid formulations developed by MGC Pharma in the treatment of glioblastoma, the most aggressive and so far therapeutically resistant primary brain tumour.

MGC Pharma has a growing patient base in Australia, the UK, Brazil and Ireland and has a global distribution footprint via an extensive network of commercial partners meaning that it is poised to supply the global market. 

Follow us through our social media channels:

Twitter: @MGC_Pharma

Facebook: @mgcpharmaceuticals

LinkedIn: MGC Pharmaceuticals Ltd.

Instagram: @mgc_pharma